Screener
Amneal Pharmaceuticals, Inc. AMRX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 39.3%+1.7pp | 38.7%+2.0pp | 36.9%+0.4pp | 36.8%+1.4pp | 37.7%+2.6pp | |
| Operating margin | 14.6%+1.4pp | 14.3%+1.6pp | 13.1%+4.1pp | 12.2%+5.2pp | 13.2%+6.5pp | |
| Net margin | 5%+4.9pp | 4%+4.5pp | 2.4%+6.6pp | 0.2%+7.1pp | 0.1%+6.8pp | |
| Returns | ||||||
| Return on invested capital | 20.3%+10.3pp | 20.1%+10.7pp | 15.7%+5.2pp | 13.4%+5.9pp | 10.1%+3.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×+0.1× | 0.8×0.0× | 0.8×+0.1× | 0.8×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.2×+0.8× | 2.5×+1.1× | 2.2×+0.8× | 2.1×+0.8× | 1.4×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 77.8×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $0.10+129% | -$0.14+66.0% | -$0.22+38.3% | -$0.34-11.7% | -$0.35-93.0% | |
| Valuation | ||||||
| Market capitalization | $5.77B+129% | $3.97B+51.0% | $3.96B+61.4% | $3.14B+22.1% | $2.55B+30.0% | |
| Price / earnings | 36.7×-711× | 32.5×— | 55×— | 532.9×— | 755×— | |
| Price / sales | 1.9×+1.0× | 1.3×+0.4× | 1.3×+0.4× | 1.1×+0.1× | 0.9×+0.1× | |
| Price / book | 174.7×— | —— | —— | —— | —— |
FAQ
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Amneal Pharmaceuticals, Inc. (AMRX) runs a 39.3% gross margin and a 14.6% operating margin, with a 5.0% net margin.
- Where do Amneal Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Amneal Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
